We're out of start-up phase: Cryptome
01 June, 2005 by Ruth BeranEighteen months after its AUD$6.6 million IPO in November 2003, Melbourne-based Cryptome Pharmaceuticals (ASX:CRP) has achieved all of the objectives listed in its IPO prospectus and claims that it is no longer in the start-up phase.
Alchemia heartened by thumbs-up for Glaxo drug
31 May, 2005 by Graeme O'NeillShares in Brisbane biopharma Alchemia (ASX:ACL) rose 7 per cent today on news that the US Food and Drug Administration has approved GlaxoSmithKline's anti-thrombotic drug Arixtra in surgical patients at high risk of life-threatening venous blood clots.
AustCancer changes name, sets course for US
31 May, 2005 by Graeme O'NeillOncology drug developer Australian Cancer Technology (ASX:ACU) has changed its name to Avantogen, and flagged its intention to relocate its headquarters to San Diego, on the US west coast, within a few years.
Tissue Therapies patent accepted in Australia
31 May, 2005 by Ruth BeranThe core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia.
Biotech pioneer BresaGen resurrected as service company
30 May, 2005 by Graeme O'NeillThe dark clouds over venerable Adelaide biopharma BresaGen (ASX:BGN) have parted, revealing a little blue sky. But the resurrected company's business plan is focused on terra firma -- it is going back to its roots as a service company.
Cryptome in deal with German biotech Xantos
27 May, 2005 by Graeme O'NeillMelbourne drug discovery biotech Cryptome Pharmaceuticals (ASX:CRP) has turned on its income tap after signing a collaboration agreement with Germany's Xantos Biomedicine to validate Xantos' lead anti-cancer molecule.
New biopharma Apollo readies for lift-off
27 May, 2005 by Graeme O'NeillSydney-based biopharma Apollo Life Sciences lodged its prospectus with the ASX yesterday to raise AUD$9.5 million from its IPO in June.
Bumper Aust cotton harvest said to validate GM technology
26 May, 2005 by Graeme O'NeillThe harvest of Australia's 2004/05 cotton crop, the first to involve full-scale production of new-generation, pest-resistant Bollgard 2 varieties, is nearing completion.
Pfizer P3 grant call nets 'massive' response
26 May, 2005 by Ruth BeranPfizer Australia has received a "massive" response to its first internal global call for submissions after it successfully won an AUD$10 million pharmaceutical partnerships program (P3) grant earlier this year.
Sirtex appoints new CEO
26 May, 2005 by Ruth BeranSydney biomedical company Sirtex Medical (ASX:SRX) has promoted Gilman Wong from chief operating officer to chief executive officer.
In brief: Psiron; Eqitx
25 May, 2005 by Staff WritersPsiron (ASX:PSX) has presented a research paper at the International Meeting on Molecular Biology of Picornaviruses showing anticancer activity of a new strain of its lead product (CVA21) against a wider range of colorectal cancer cells.
Microarrays provide clues to drug side effects
25 May, 2005 by Graeme O'NeillThe US Food and Drug Administration and Applied Biosystems researchers have recently collaborated on a comparative study of the genetic effects of the three commercialised glitazone drugs, using the company's microarray platform technology.
Bionomics acquires Iliad Chemicals
25 May, 2005 by Ruth BeranBionomics (ASX:BNO) has acquired unlisted Melbourne discovery company Iliad Chemicals for 40.9 million Bionomics shares - approximately AUD$6.1 million at current market prices.
Ventracor implants first European patient
24 May, 2005 by Renate KrelleSydney's Ventracor (ASX:VCR) has announced the first European implant of its VentrAssist device as part of its CE Mark Trial.
Genesis flush after ArboGen stoush settles
24 May, 2005 by Graeme O'NeillAuckland-based biotech Genesis Research (ASX/NZSX:GEN) has received a valuable boost to its bottom line after an out-of-court settlement of its long-running dispute with former US ally, Delaware-based forestry biotech company ArboGen.
